Pay in 4 interest-free payments of $5.23 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Reviewed by the PeptideMind Team Updated July 28, 2026 PE-22-28 Peptide Dosage Guide, Benefits & Side Effects PE-22-28 (Mini-Spadin) dosage guide and protocol: TREK-1 antagonist peptide studied for rapid antidepressant-like effects, mood, memory, and hippocampal neurogenesis
The FDA label states that providers should consider discontinuing treatment if patients do not achieve at least 5% weight loss after 12 weeks at the maintenance dose, as continued use is unlikely to provide meaningful clinical benefit
We identified that GLP-1R agonism reduced ethanol consumption, mitigated ethanol-induced upregulation of several liver metabolizing enzymes, including Cyp2e1 and also reduced Cyp2e1 independent of ethanol intake
It allows for tailored dosing or combinations that may not be available in commercial formulations
